Innovent's Jaypirca Gains Expanded CLL/SLL Approval in China…

Event summary

China's NMPA approved Jaypirca® (pirtobrutinib) for CLL/SLL across all treatment lines on September 28, 2026.
Approval supported by Phase 3 BRUIN CLL-313 and BRUIN CLL-314 trials showing 80.1% reduction in disease progression risk vs. chemoimmunotherapy.
Pirtobrutinib demonstrated non-inferiority to ibrutinib in treatment-naïve patients with higher overall response rate.
Innovent and Lilly collaborate on development and commercialization in China.

The big picture

This approval positions Jaypirca as a potential frontline treatment option for CLL/SLL in China, challenging existing covalent BTK inhibitors. The non-covalent mechanism offers potential advantages in efficacy and tolerability, which could reshape treatment paradigms for this common adult leukemia. Innovent's collaboration with Lilly underscores the strategic importance of this market, with approximately 100,000 new CLL/SLL cases globally each year.

What we're watching

Market Penetration: How quickly Innovent can expand Jaypirca's reach across all CLL/SLL treatment lines in China's competitive oncology market.
Clinical Data Maturation: Whether pirtobrutinib's progression-free survival benefits will become statistically significant in ongoing trials.
Commercial Strategy: The pace at which Innovent leverages its oncology commercial capabilities to drive patient access and adoption.